OX-MPI - Microvascular disease
|Development phase||Finalized phase 1, will enter phase 2 in Q4 2020|
|Expected filing with FDA||-|
|In-house or partnership||Partnership with Gesynta Pharma AB|
Several severe microvascular complications currently have few or no approved pharmacological treatment options.
Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions.
More effective and/or safer than currently approved treatments.